ArticleScientific reports2020
Biomimetic cellular vectors for enhancing drug delivery to the lungs.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Decoy Nanoparticles and Protein Corona Modulation: A Novel Frontier in Sepsis Treatment.International journal of nanomedicine · 2026Review
- Advanced cell-derived drug delivery systems for pulmonary diseases: from bench to bedside.Drug delivery · 2025Review
- Therapeutic strategies based on macrophages and their derivatives: Targeted drug delivery platforms and disease treatment.Journal of pharmaceutical analysis · 2025Review
- Harnessing macrophages for precision drug delivery and cancer therapy: Strategies, advances and challenges.Materials today. Bio · 2025Review
- Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective.Drug delivery · 2023Review
- Biomimetic Systems Involving Macrophages and Their Potential for Targeted Drug Delivery.Biomimetics (Basel, Switzerland) · 2023Review
- Bacterial outer membrane vesicles-based therapeutic platform eradicates triple-negative breast tumor by combinational photodynamic/chemo-/immunotherapy.Bioactive materials · 2023Article
- Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment.Journal of nanobiotechnology · 2022Review
- Cells-Based Drug Delivery for Cancer Applications.Nanoscale research letters · 2021Review
- Engineering MacrophagesFrontiers in oncology · 2021Review
- Recent Advances in Macrophage-Mediated Drug Delivery Systems.International journal of nanomedicine · 2021Review
- Cell Membrane-Based Biomimetic Nanoparticles and the Immune System: Immunomodulatory Interactions to Therapeutic Applications.Frontiers in bioengineering and biotechnology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Despite recent advances in drug delivery, the targeted treatment of unhealthy cells or tissues continues to remain a priority. In cancer (much like other pathologies), delivery vectors are designed to exploit physical and biological features of unhealthy tissues that are not always homogenous across the disease. In some cases, shifting the target from unhealthy tissues to the whole organ can represent an advantage. Specifically, the natural organ-specific retention of nanotherapeutics following intravenous administration as seen in the lung, liver, and spleen can be strategically exploited to enhance drug delivery. Herein, we outline the development of a cell-based delivery system using macrophages as a delivery vehicle. When loaded with a chemotherapeutic payload (i.e., doxorubicin), these cellular vectors (CELVEC) were shown to provide continued release within the lung. This study provides proof-of-concept evidence of an alternative class of biomimetic delivery vectors that capitalize on cell size to provide therapeutic advantages for pulmonary treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.